Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a open-label pilot study of MYK-224 in obstructive hypertrophic cardiomyopathy
2022-001292-14Phase 2Active
- Sponsor
- MyoKardia
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of BMS-986435 in hypertrophic cardiomyopathy (HCM), sponsored by MyoKardia. Primary endpoint: Safety and tolerability of MYK-224. Started Sep 2022; status: active.
02
Drugs
BMS-986435
03
Conditions
hypertrophic cardiomyopathy (HCM)
Beyond the preview
Go deeper on 2022-001292-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001292-14.